Skip to content

Association between anti-thymocyte globulin exposure and clinical outcomes of adult undergoing haploidentical hematopoietic stem cell transplantation with myeloablative conditioning: a pharmacokinetic-guided study.

Nov 2026 · Transplantation and Cellular Therapy · 0 citations · 28 references
Medicine

Abstract

Background

Rabbit antithymocyte globulin (rATG) plays a critical role in preventing graft-versus-host disease (GVHD) after haploidentical hematopoietic stem cell transplantation (haplo-HSCT). However, conventional weight-based dosing results in substantial interpatient variability in active rATG exposure, potentially affecting transplant outcomes. Defining an optimal exposure range may improve the balance between GVHD prevention and post-transplant survival.

Objective

To characterize active rATG exposure and identify a candidate optimal exposure range associated with improved survival and reduced GVHD in patients with acute leukemia undergoing haplo-HSCT. STUDY

Design

This retrospective, single-center study included 119 patients with acute leukemia who underwent haplo-HSCT between June 2020 and March 2023. Active rATG concentrations were measured using flow cytometry in 1,919 blood samples, and exposure was quantified as the area under the concentration-time curve (AUC). Restricted cubic spline (RCS) analyses were performed to explore exposure-outcome relationships. Clinical outcomes were compared across exposure groups, and Cox proportional hazards regression was used to identify prognostic factors.

Results

RCS analyses revealed significant nonlinear associations between post-HSCT rATG exposure and overall survival (OS; P for nonlinearity =0.018) and grade II-IV acute GVHD (aGVHD; P for nonlinearity = 0.006), supporting a candidate optimal AUC range of 52-78 AU/mL/day. Patients were stratified into low- (<52 AU/mL/day; n=17), optimal- (52-78 AU/mL/day; n=48), and high-exposure (>78 AU/mL/day; n=54) groups. The 2-year OS rates were 58.8%, 91.5%, and 72.1%, respectively (P=0.009), while leukemia-free survival (LFS) rates were 58.8%, 87.2%, and 66.7% (P=0.019). Corresponding GVHD-free/relapse-free survival rates were 29.4%, 74.5%, and 53.7% (P < 0.001). The 100-day cumulative incidence of grade II-IV aGVHD was significantly lower in the optimal-exposure group (16.7%) than in the low- (52.9%) and high-exposure (31.5%) groups (overall P=0.012). No statistically significant differences in cytomegalovirus or Epstein-Barr virus reactivation were observed among groups (P=0.519 and P=0.068, respectively). Multivariable Cox regression confirmed a significant association between post-HSCT rATG exposure and OS (overall P=0.035). Compared with optimal exposure, low exposure was associated with a significantly increased mortality risk (hazard ratio=4.81, 95% confidence interval: 1.45-16.01, P = 0.010).

Conclusion

In adults with acute leukemia undergoing ATG-based myeloablative haplo-HSCT, a post-transplant active rATG AUC of 52-78 AU/mL/day was associated with favorable survival outcomes and reduced aGVHD incidence, without increasing viral reactivation risks. These findings support further development of pharmacokinetic-guided ATG dosing strategies, although prospective external validation across different transplant platforms, conditioning regimens, and graft sources is required.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.